US bill seeks to improve use of accelerated approval pathway for ultra-rare drugs
This article was originally published in SRA
US lawmakers have introduced a bill designed to improve access to the Food and Drug Administration's accelerated approval pathway for medicines designed to treat life-threatening, ultra-rare diseases1,2.
You may also be interested in...
The latest list of marketing authorization applications under review by the European Medicines Agency includes filings for eight new products.
Viela and Roche both now have marketing applications that are being reviewed by the European Medicines Agency. If approved in the EU, their products will compete with Alexion’s blockbuster Soliris.
Most of the products currently supplied under Australia’s custom-made medical device exemption will no longer be eligible for supply in this way.